Loading...
Market
What will be the first use case of Neuralink's 'Blindsight' product by the end of 2024?
2
Resolution / Starting Odds
Restoring eyesight to a blind individual • 25%
Enhancing vision for partially sighted individuals • 25%
Other medical applications • 25%
No application by end of 2024 • 25%
Official announcements from Neuralink or verified news reports
Story
Neuralink's Second Implant Success: Alex Plays Games Using Brain, No Thread Retraction
Aug 21, 2024, 09:55 PM
Elon Musk's Neuralink has successfully completed a second trial implant with a patient named Alex. The implant allows Alex to control digital devices using his brain, demonstrated by his ability to play Counter-Strike 2 and use CAD software without traditional peripherals. Alex designed a custom mount for his Neuralink charger using Fusion 360, which was 3D printed and integrated into his setup. Musk stated that Neuralink aims to have a high single-digit number of patients this year, pending regulatory approvals, with plans to expand to thousands in the future. The company also announced its next product, 'Blindsight,' intended to restore eyesight to blind individuals. The second trial implant went well, with no thread retraction issue reported.
View original story
Similar markets
Infrared vision capability • 25%
Ultraviolet vision capability • 25%
Both infrared and ultraviolet vision capabilities • 25%
Neither capability • 25%
Yes • 50%
No • 50%
Significant improvement in vision • 25%
Moderate improvement in vision • 25%
No noticeable improvement • 25%
Negative side effects • 25%
Medical (e.g., helping paralyzed individuals) • 25%
Gaming • 25%
Communication • 25%
Other • 25%
Assistive technology for paralysis • 25%
Cognitive enhancement • 25%
Medical treatment for neurological disorders • 25%
Other • 25%
Yes • 50%
No • 50%
High adoption (over 10,000 units sold) • 25%
Moderate adoption (1,000-10,000 units sold) • 25%
Low adoption (100-1,000 units sold) • 25%
Very low adoption (less than 100 units sold) • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%